Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Serum BCMA: a new prognostic marker for PFS in myeloma

James Berenson • 14 Sep 2019
IMW 2019
Multiple Myeloma

James Berenson, MD, from The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, speaks at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, about monitoring serum BCMA levels to indicate prognosis in multiple myeloma.

More from James Berenson

1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
1:08
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals